AbbVie (NYSE: ABBV), a major U.S. pharmaceutical company, has announced the acquisition of Celsius Therapeutics Inc., a biotechnology firm specialized in developing therapies for anti-inflammatory diseases. The transaction involves a cash payment of USD 250 million to acquire all equity interests in Celsius.
Through this acquisition, AbbVie will obtain control of CEL383, a first-in-class anti-TREM1 antibody and the lead pipeline candidate of Celsius. CEL383 has completed a Phase I clinical study for the treatment of inflammatory bowel disease (IBD). TREM1 signaling plays a role in the reduction of multiple inflammatory mediators, which are highly relevant to various inflammatory conditions in a clinical setting.- Flcube.com
